128 related articles for article (PubMed ID: 28259898)
1. An improved method for the establishment of a model of Graves' disease in BALB/c mice.
Zheng W; Wang R; Tan J; Li N; Meng Z
Mol Med Rep; 2017 Apr; 15(4):1471-1478. PubMed ID: 28259898
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous induction of Graves' hyperthyroidism and Graves' ophthalmopathy by TSHR genetic immunization in BALB/c mice.
Xia N; Ye X; Hu X; Song S; Xu H; Niu M; Wang H; Wang J
PLoS One; 2017; 12(3):e0174260. PubMed ID: 28319174
[TBL] [Abstract][Full Text] [Related]
3. [Effect of Jiakangning Capsule on Thyroid Function and Akt/mTOR Signal Pathway of Graves' Disease Mice: an Experimental Study].
Li QM; Wei JP; Li M; Meng SH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Sep; 35(9):1119-24. PubMed ID: 26591370
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of an animal model for thyroid associated ophthalmopathy by treatment of mice with human thyrotropin receptors-activated splenocytes].
Zhang L; Liu C; Zhang H; He Y; Zhan SH
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1073-7. PubMed ID: 17415963
[TBL] [Abstract][Full Text] [Related]
5. An improved Graves' disease model established by using in vivo electroporation exhibited long-term immunity to hyperthyroidism in BALB/c mice.
Kaneda T; Honda A; Hakozaki A; Fuse T; Muto A; Yoshida T
Endocrinology; 2007 May; 148(5):2335-44. PubMed ID: 17255207
[TBL] [Abstract][Full Text] [Related]
6. [An exploration of induction methodology and experimental duration of Graves disease animal model].
Wu LP; Shi BY; Xun LR; Guo LY; Yang J; Xu L
Zhonghua Nei Ke Za Zhi; 2012 Oct; 51(10):793-7. PubMed ID: 23290979
[TBL] [Abstract][Full Text] [Related]
7. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
8. An improved mouse model of Graves disease by once immunization with Ad-TSHR289.
Tang Y; Zhu X; Feng H; Zhu L; Fu S; Kong B; Liu X
Endocr J; 2019 Sep; 66(9):827-835. PubMed ID: 31217394
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease.
Wang X; Liu W; Rui Z; Zheng W; Tan J; Li N; Yu Y
Endokrynol Pol; 2021; 72(6):592-600. PubMed ID: 34647608
[TBL] [Abstract][Full Text] [Related]
10. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
11. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
12. Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination.
Rao PV; Watson PF; Weetman AP; Carayanniotis G; Banga JP
Endocrinology; 2003 Jan; 144(1):260-6. PubMed ID: 12488353
[TBL] [Abstract][Full Text] [Related]
13. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease.
Kita M; Ahmad L; Marians RC; Vlase H; Unger P; Graves PN; Davies TF
Endocrinology; 1999 Mar; 140(3):1392-8. PubMed ID: 10067867
[TBL] [Abstract][Full Text] [Related]
14. Unaltered thyroid function in mice responding to a highly immunogenic thyrotropin receptor: implications for the establishment of a mouse model for Graves' disease.
Carayanniotis G; Huang GC; Nicholson LB; Scott T; Allain P; McGregor AM; Banga JP
Clin Exp Immunol; 1995 Feb; 99(2):294-302. PubMed ID: 7851025
[TBL] [Abstract][Full Text] [Related]
15. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dihydrotestosterone on CostimulatoryMolecules in a Mouse Model of Graves' Disease.
Liu LY; Shi BY; Zhao FY; Hou P; Liu S; Liu XM; Wu LP
Chin Med Sci J; 2020 Sep; 35(3):215-225. PubMed ID: 32972499
[TBL] [Abstract][Full Text] [Related]
17. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
18. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders.
Cardia MS; Lima N; Knobel M; Medeiros-Neto G
Thyroid; 2004 Apr; 14(4):295-300. PubMed ID: 15142363
[TBL] [Abstract][Full Text] [Related]
20. Mouse model of Graves' orbitopathy induced by the immunization with TSHR A and IGF-1R α subunit gene.
Wu R; Li N; Wang X; Wang S; Tan J; Wang R; Zheng W
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38662129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
